926 resultados para Chief Scientist Office (CSO)
Resumo:
During Leg ANT-XXIII/9 on the 31st March 2007 the German research vessel Polarstern mapped a significant bathymetric feature with its swath sonar system at the north-west margin of the Kerguelen Plateau. Due to the fact, that the feature was discovered just a month after the third IPY 2007/2008 has started, it was named after Graf Wilczek who, together with Carl Weyprecht, had promoted the first IPY. The undersea feature name proposal was officialy accepted by the GEBCO Sub-Committee on Undersea Feature Names (SCUFN) at its 20th meeting in late July and was added to the GEBCO Gazetteer of UFN (http://www.iho.shom.fr/COMMITTEES/GEBCO/SCUFN/scufn_intro.htm). ______________ Graf Hans Wilczek (Notation of the name from the book of Wilczek's daughter Elisabeth Kinsky- Wilczek). The Austrian naval hero Tegetthoff in 1871 planned an expedition to the southern hemisphere. The geophysicist G. Neumayer (1826-1909) already was selected as its chief scientist. Also the naval officer Carl Weyprecht (1838-1881) and the mountaineer Julius Payer (1841-1915) were to participate. Because of the sudden death of Tegettoff the project came to a halt and eventually was cancelled. By support of the well known geographer August Petermann (1822-1878) Weyprecht and Payer made a voyage into the Barents Sea which made them believe having seen the "open polar sea". An additional undertaking to confirm and to extend the find was obvious. At this stage of the affair count Hans Wilczek (1837-1922) got involved. He not only fostered a new expedition with a considerable sum of money, but he participated in commanding a support vessel to Novaya Zemlya. Wilczek managed to get home but the expedition vessel under Weyprecht's command became imprisoned in the pack for two years and at least had to be abandoned. After an adventurous trip back to civilisation Weyprecht changed his mind in what he considered the best way of polar research. Together with Wilczek in 1875 he started the promotion of international station-based polar exploration - the IPY was born. Wilczek guaranteed the constitution of an Austrian station on Novaya Zemlya and was ready to winter over there personally. Because of several political and other obstructions the beginning of the IPY was delayed till 1882. Wilczek's friend Weyprecht had passed away already. The command of the Austrian station, eventually erected on Jan Mayen, was given to Emil v. Wohlgemuth (1843-1896). Wilczek financed the main part of the Austrian IPY participation. Wilczek is described as honest and popular. On the one hand acquainted with the most prominent persons of his days, he respected everybody and had many relationships with scientists and artists. There is a kind of autobiography under the title: Hans Wilczek erzählt seinen Enkeln Erinnerungen aus seinem Leben (Hans Wilczek tells his grandchildren reminiscences from his life); edited by his daughter Elisabeth Kinsky-Wilczek, Graz 1933, 502 p. The book is available in an English version: Happy Retrospect - the Reminiscences of Count Wilczek 1837-1922, Bell and Sons, London 1934, 295 p.
Resumo:
Acknowledgments Financial Support: HERU and HSRU receive a core grant from the Chief Scientist’s Office of the Scottish Government Health and Social Care Directorates, and the Centre for Clinical epidemiology & Evaluation is funded by Vancouver Coastal Health Authority. The model used for the illustrative case study in this paper was developed as part of a NHS Technology Assessment Review, funded by the National Institute for Health Research (NIHR) Health Technology Assessment Program (project number 09/146/01). The views and opinions expressed in this paper are those of the authors and do not necessarily reflect those of the Scottish Government, NHS, Vancouver Coastal Health, NIHR HTA Program or the Department of Health. The authors wish to thank Kathleen Boyd and members of the audience at the UK Health Economists Study Group, for comments received on an earlier version of this paper. We also wish to thank Cynthia Fraser (University of Aberdeen) for literature searches undertaken to inform the manuscript, and Mohsen Sadatsafavi (University of British Columbia) for comments on an earlier draft
Resumo:
© The Author(s) 2014. Acknowledgements We thank the Information Services Division, Scotland, who provided the SMR01 data, and NHS Grampian, who provided the biochemistry data. We also thank the University of Aberdeen’s Data Management Team. Funding This work was supported by the Chief Scientists Office for Scotland (grant no. CZH/4/656).
Resumo:
This is a report about a joint scientific venture of German and Norwegian Institutes in an area between Latitude = 66°45' N and 68°30' N and Longitude 1.0° E to 7°30' W. The chief scientist's report gives an outline of the cruise. The preliminary contributions by the scientists deal with results of gravity at sea, magnetic and geothermic measurements, the seismic shooting, results of continuous seismic reflection work, some refraction seismic results and with the observations of the ship's weather station.
Resumo:
ACKNOWLEDGEMENTS: The Medman study was funded by the Department of Health for England and Wales and managed by a collaboration of the National Pharmaceutical Association, the Royal Pharmaceutical Society of Great Britain, the Company Chemist Association and the Co-operative Pharmacy Technical Panel, led by the Pharmaceutical Services Negotiating Committee. The research in this paper was undertaken while the lead author MT was undertaking a doctoral research fellowship jointly funded by the Economic and Social Research Council (ESRC) and the Medical Research Council (MRC). The Health Economics Research Unit (HERU), University of Aberdeen is funded by the Chief Scientific Office of the Scottish Government Health and Social Care Directorate.
Resumo:
Crown Copyright © 2015. Published by Elsevier Ireland Ltd. All rights reserved. Acknowledgements The Aberdeen birth Cohort Studies were established with grants to Lawrence Whalley by the Henry Smith Charity, the UK Biotechnology and Biological Sciences Research Council and a Professorial Clinical Fellowship Award from the Wellcome Trust. The imaging studies reported here were supported by grants to all three authors by the Chief Scientist Organisation of the Scottish Health Department and Alzheimer Research UK. We are grateful to the volunteers in the Aberdeen 1921 and 1936 Birth Cohort Studies and to our research colleagues in the Aberdeen biomedical Imaging Centre (Drs. Ahearn, Waiter, and Mustafa) and our long-term collaborators in the University of Edinburgh (Professors Deary and Starr at www.ccace.ed.ac.uk).
Resumo:
The primary objective is to investigate the main factors contributing to GMS expenditure on pharmaceutical prescribing and projecting this expenditure to 2026. This study is located in the area of pharmacoeconomic cost containment and projections literature. The thesis has five main aims: 1. To determine the main factors contributing to GMS expenditure on pharmaceutical prescribing. 2. To develop a model to project GMS prescribing expenditure in five year intervals to 2026, using 2006 Central Statistics Office (CSO) Census data and 2007 Health Service Executive{Primary Care Reimbursement Service (HSE{PCRS) sample data. 3. To develop a model to project GMS prescribing expenditure in five year intervals to 2026, using 2012 HSE{PCRS population data, incorporating cost containment measures, and 2011 CSO Census data. 4. To investigate the impact of demographic factors and the pharmacology of drugs (Anatomical Therapeutic Chemical (ATC)) on GMS expenditure. 5. To explore the consequences of GMS policy changes on prescribing expenditure and behaviour between 2008 and 2014. The thesis is centered around three published articles and is located between the end of a booming Irish economy in 2007, a recession from 2008{2013, to the beginning of a recovery in 2014. The literature identified a number of factors influencing pharmaceutical expenditure, including population growth, population aging, changes in drug utilisation and drug therapies, age, gender and location. The literature identified the methods previously used in predictive modelling and consequently, the Monte Carlo Simulation (MCS) model was used to simulate projected expenditures to 2026. Also, the literature guided the use of Ordinary Least Squares (OLS) regression in determining demographic and pharmacology factors influencing prescribing expenditure. The study commences against a backdrop of growing GMS prescribing costs, which has risen from e250 million in 1998 to over e1 billion by 2007. Using a sample 2007 HSE{PCRS prescribing data (n=192,000) and CSO population data from 2008, (Conway et al., 2014) estimated GMS prescribing expenditure could rise to e2 billion by2026. The cogency of these findings was impacted by the global economic crisis of 2008, which resulted in a sharp contraction in the Irish economy, mounting fiscal deficits resulting in Ireland's entry to a bailout programme. The sustainability of funding community drug schemes, such as the GMS, came under the spotlight of the EU, IMF, ECB (Trioka), who set stringent targets for reducing drug costs, as conditions of the bailout programme. Cost containment measures included: the introduction of income eligibility limits for GP visit cards and medical cards for those aged 70 and over, introduction of co{payments for prescription items, reductions in wholesale mark{up and pharmacy dispensing fees. Projections for GMS expenditure were reevaluated using 2012 HSE{PCRS prescribing population data and CSO population data based on Census 2011. Taking into account both cost containment measures and revised population predictions, GMS expenditure is estimated to increase by 64%, from e1.1 billion in 2016 to e1.8 billion by 2026, (ConwayLenihan and Woods, 2015). In the final paper, a cross{sectional study was carried out on HSE{PCRS population prescribing database (n=1.63 million claimants) to investigate the impact of demographic factors, and the pharmacology of the drugs, on GMS prescribing expenditure. Those aged over 75 (ẞ = 1:195) and cardiovascular prescribing (ẞ = 1:193) were the greatest contributors to annual GMS prescribing costs. Respiratory drugs (Montelukast) recorded the highest proportion and expenditure for GMS claimants under the age of 15. Drugs prescribed for the nervous system (Escitalopram, Olanzapine and Pregabalin) were highest for those between 16 and 64 years with cardiovascular drugs (Statins) were highest for those aged over 65. Females are more expensive than males and are prescribed more items across the four ATC groups, except among children under 11, (ConwayLenihan et al., 2016). This research indicates that growth in the proportion of the elderly claimants and associated levels of cardiovascular prescribing, particularly for statins, will present difficulties for Ireland in terms of cost containment. Whilst policies aimed at cost containment (co{payment charges, generic substitution, reference pricing, adjustments to GMS eligibility) can be used to curtail expenditure, health promotional programs and educational interventions should be given equal emphasis. Also policies intended to affect physicians prescribing behaviour include guidelines, information (about price and less expensive alternatives) and feedback, and the use of budgetary restrictions could yield savings.
Resumo:
Background: increasing numbers of patients are surviving critical illness, but survival may be associated with a constellation of physical and psychological sequelae that can cause on going disability and reduced health-related quality of life. Limited evidence currently exists to guide the optimum structure, timing, and content of rehabilitation programmes. There is a need to both develop and evaluate interventions to support and expedite recovery during the post-ICU discharge period. This paper describes the construct development for a complex rehabilitation intervention intended to promote physical recovery following critical illness. The intervention is currently being evaluated in a randomised trial (ISRCTN09412438; funder Chief Scientists Office, Scotland). Methods: the intervention was developed using the Medical Research Council (MRC) framework for developing complex healthcare interventions. We ensured representation from a wide variety of stakeholders including content experts from multiple specialties, methodologists, and patient representation. The intervention construct was initially based on literature review, local observational and audit work, qualitative studies with ICU survivors, and brainstorming activities. Iterative refinement was aided by the publication of a National Institute for Health and Care Excellence guideline (No. 83), publicly available patient stories (Healthtalkonline), a stakeholder event in collaboration with the James Lind Alliance, and local piloting. Modelling and further work involved a feasibility trial and development of a novel generic rehabilitation assistant (GRA) role. Several rounds of external peer review during successive funding applications also contributed to development. Results: the final construct for the complex intervention involved a dedicated GRA trained to pre-defined competencies across multiple rehabilitation domains (physiotherapy, dietetics, occupational therapy, and speech/language therapy), with specific training in post-critical illness issues. The intervention was from ICU discharge to 3 months post-discharge, including inpatient and post-hospital discharge elements. Clear strategies to provide information to patients/families were included. A detailed taxonomy was developed to define and describe the processes undertaken, and capture them during the trial. The detailed process measure description, together with a range of patient, health service, and economic outcomes were successfully mapped on to the modified CONSORT recommendations for reporting non-pharmacologic trial interventions. Conclusions: the MRC complex intervention framework was an effective guide to developing a novel post-ICU rehabilitation intervention. Combining a clearly defined new healthcare role with a detailed taxonomy of process and activity enabled the intervention to be clearly described for the purpose of trial delivery and reporting. These data will be useful when interpreting the results of the randomised trial, will increase internal and external trial validity, and help others implement the intervention if the intervention proves clinically and cost effective.
Resumo:
Pay roll voucher #12 from the Engineer Department of Port Dalhousie and Thorold Railway Extension for the office approved by F. Shanly, chief engineer, April, 1857.
Resumo:
Pay roll voucher #16 from the Engineer Department of Port Dalhousie and Thorold Railway Extension, for the office approved by F. Shanly, chief engineer, May 30, 1857.
Resumo:
Pay roll voucher #19 from the Port Dalhousie and Thorold Railway Extension, for the office approved by F. Shanly, chief engineer (copy), July 1, 1857.
Resumo:
Pay roll voucher #24 from the Engineer Department of Port Dalhousie and Thorold Railway Extension, for the office, for the month of July, 1857 approved by F. Shanly, chief engineer (copy), July 31, 1857.
Resumo:
Mode of access: Internet.
Resumo:
Seals of Dept. of State, War Dept., and International Military Tribunal, on t.p.
Resumo:
Title varies slightly.